Investor Presentation
Released
Released
Announcement PDF
BUSINESS UPDATE &
H1 2016 FINANCIAL RESULTS
INVESTOR PRESENTATION
29 FEBRUARY 2016
COGSTATE HIGHLIGHTS
•
Cogstate is a leader in Cognitive Assessment
•
Cognitive Assessment and Training Market is projected to
grow from USD 2.4 Billion in 2015 to 7.5 Billion by 20201
•
94% of revenue in H1FY16 comes from clinical trials,
where revenue is driven by volume and size of trials
•
Outsourcing growth trends to continue in Clinical Trials2
•
Long life contracts (>12mths) provides revenue certainty
•
Cogstate’s customers are some of the world’s largest
pharmaceutical and biotech companies and CRO’s
•
Strong legacy of scientific excellence facilitating current
focus on business development and product development
•
H1 FY16 results highlight Cogstate has transitioned to
profitability and that strong growth momentum continues
1.
2.
© 2015 Cogstate Ltd. All rights reserved.
Market Research Report: Cognitive Assessment and Training Market by Assessment Type (Pen & Paper Based, Hosted,
Biometrics), Service, Application (Clinical Trials, Classroom Learning, Brain Training, Corporate Learning, Academic
Research), Vertical and Region - Global Forecast to 2020", published by MarketsandMarkets
The global clinical trial service market predicted to reach more than $64B by 2020, representing CAGR of 9% with close to 75%
of trial predicted to be outsourced to CROs. Source: Research and Markets “The New Trends of Global Clinical Development
Outsourcing Market” – 30 June 2015.
2
© 2015 Cogstate Ltd. All rights reserved.
3
CLINICAL TRIALS PORTFOLIO OF SERVICES FOR COGNITIVE
ASSESSMENT IS THE DEEPEST IN THE INDUSTRY
“
From well-validated computerised batteries to expert support
for traditional paper-and-pencil tests, science, innovation and
excellence in delivery are at the core of everything we do.
© 2015 Cogstate Ltd. All rights reserved.
”
4
H1 FY16 RESULTS AT A GLANCE
Revenue of
A$13.0m (up
109% PCP)
Gross Margin 57%
(within target range
57-60%)
Record pipeline of
contracted future
revenue A$52.1m
EBIT of A$1.1m,
NPAT of A$2.6m,
EPS of $0.024
FY16 H1
FY15 H1
Change
A$ millions
A$ millions
A$ millions
Clinical Trials Revenue
12.2
5.6
6.6
Total Revenue
13.0
6.2
6.8
EBIT
1.1
-2.9
4.0
Net Profit After Tax*
2.6
-2.7
5.3
*FY16 H1 includes A$1.5m Income Tax Benefit relating to the recognition of carried-forward tax losses, predominantly relating to tax losses in the USA group.
© 2015 Cogstate Ltd. All rights reserved.
5
CONTINUED FINANCIAL IMPROVEMENT
FY16
1ST HALF
$’000,000
FY15
2ND HALF
$’000,000
FY15
1ST HALF
$’000,000
· Revenue
12.24
9.62
5.57
· Cost of Sales
-5.23
-3.78
-2.95
7.01
5.84
2.62
0.01
0.07
0.10
7.02
5.91
2.72
SUMMARY FINANCIAL RESULTS
Clinical Trials
Gross Margin
· Net Recovery of Pass-through Costs
Total Clinical Trials Contribution
Precision Recruitment Contribution
0.60
0.21
0.23
Healthcare Contribution
-0.16
-0.13
-0.10
Sport Contribution
-0.03
-0.02
-0.09
Total Business Unit Contribution
7.42
5.97
2.76
Overhead Costs – Continuing Operations
-6.46
-6.71
-5.62
-
-
-0.34
Overhead Costs – Discontinued Operations
Other Income
0.10
0.70
0.43
EBITA
1.06
-0.04
-2.77
Amortisation
0.00
-0.14
-0.14
Impairment of Assets
0.00
-2.16
0.00
EBIT
1.06
-2.35
-2.92
Interest Income
0.04
0.04
0.08
Interest Expense
0.00
-0.04
-0.02
Profit / (Loss) Before Tax
1.10
-2.35
-2.86
Income Tax Benefit / (Expense)
1.46
-0.05
0.20
Profit / (Loss) After Tax
2.56
-2.40
-2.66
© 2015 Cogstate Ltd. All rights reserved.
6
DRIVING THE MOMENTUM
1
2
3
EXECUTING
COMMERCIAL
STRATEGY
FAVOURABLE
INDUSTRY
TRENDS
EXPANDING
PORTFOLIO OF
SOLUTIONS
© 2015 Cogstate Ltd. All rights reserved.
•
Targeted sales strategy delivering results
– a 4x increase in proposals vs PCP
•
Fully resourced commercial team as of
Oct 2015 + utilisation of scientific subject
matter experts
•
Expanded reach: Identification of RFPs
in multiple indications across pharma,
biotech and CROs
•
Strong operational delivery driving
repeat business
7
DRIVING THE MOMENTUM
1
2
3
EXECUTING
COMMERCIAL
STRATEGY
FAVOURABLE
INDUSTRY
TRENDS
EXPANDING
PORTFOLIO OF
SOLUTIONS
© 2015 Cogstate Ltd. All rights reserved.
•
Alzheimer’s/Dementia: Increased trial
activity in early stage disease / prevention
•
Major Psychiatric Disorders (SZ, MDD):
Increase in research activity
•
Cognitive Safety Concerns: Regulatory
requirements in paediatric trials;
neurotoxicity concerns in oncology and
cardiometabolic drugs
•
Growing Interest in Computerised
Assessments and hybrid approaches vs.
only Paper-and-Pencil
8
DRIVING THE MOMENTUM
1
2
3
EXECUTING
COMMERCIAL
STRATEGY
FAVOURABLE
INDUSTRY
TRENDS
EXPANDING
PORTFOLIO OF
SOLUTIONS
© 2015 Cogstate Ltd. All rights reserved.
•
Breadth of services and expertise in
Clinical Trials to provide full service
support for computerised or P&P scales
Allows Cogstate to deliver cognitive
outcome measures regardless of the fitfor-purpose approach selected for the
trial
Key new hires in Scales Management,
Rater Training, Paediatric Assessments
• On-line pre-screening solutions for
patient recruitment –Precision
Recruitment
9
INVESTING IN GROWTH AREAS
Cogstate has focused its R&D efforts towards specific indications that
are expected to deliver commercial returns
•
For a number of years, Cogstate has supported academic KOLs (key
opinion leaders) and their research in Alzheimer’s disease
–
•
Alzheimer’s related studies have accounted for approx. 45% of sales contract value in FY15
and FY16 YTD.
In recent years, Cogstate has invested in the area of oncology
–
We have collaborated with KOLs and provided our tests to 5 major academic studies through
institutions such as St Jude’s Children’s Research Hospital (world leaders in childhood
cancer research) and a number of National Cancer Institute funded consortia such as the
The Children’s Oncology Group and Radiation Therapy Oncology Group.
–
These collaborations have been critical for validating our tools in these populations and have
allowed us to better understand their utility in clinical trials.
–
In FY15, oncology trials made up just 5% of the value of sales contracts. In FY16 YTD,
we’ve seen oncology trials make up 20% of the value of contracts signed.
© 2015 Cogstate Ltd. All rights reserved.
10
CONTRACTED REVENUE CONTINUES TO GROW
“
Over the last six quarters, the growth in our
pipeline of contracted future revenue has
outpaced our strong revenue growth. This
augurs well for ongoing positive revenue
momentum in our business.”
© 2015 Cogstate Ltd. All rights reserved.
11
SALES MOMENTUM CONTINUES TO BUILD
VALUE OF CLINICAL TRIALS
CONTRACTS SIGNED
26
24
Record Clinical Trials sales contracts
signed in FY15, totaling US$23.7m,
an increase of 165% (PCP
US$9.0m)
22
20
US$ Millions
18
16
14
Sales contracts signed FYTD
totaling US$20.6m, including
US$16.6m signed in H1
12
10
8
6
4
2
FY09
FY10
© 2015 Cogstate Ltd. All rights reserved.
FY11
FY12
FY13
FY14
FY15
FY16
YTD
12
DRIVING FUTURE REVENUE GROWTH
CLINICAL TRIALS CONTRACTED REVENUE
25,000,000
FY16 began with a pipeline of
contracted revenue of A$10.9m,
which was significantly ahead of
where we started FY15
20,000,000
15,000,000
10,000,000
5,000,000
FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY19 FY20 FY21
Revenue contracted at beginning of year
© 2015 Cogstate Ltd. All rights reserved.
Revenue from contracts signed during the year
*As at 17 February 2016
13
DRIVING FUTURE REVENUE GROWTH
CLINICAL TRIALS CONTRACTED REVENUE
25,000,000
US$20.6m of sales contracts
signed since 1 July 2015 has
added A$12.4m to contracted
FY16 revenue
20,000,000
15,000,000
10,000,000
5,000,000
FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY19 FY20 FY21
Revenue contracted at beginning of year
© 2015 Cogstate Ltd. All rights reserved.
Revenue from contracts signed during the year
*As at 17 February 2016
14
DRIVING FUTURE REVENUE GROWTH
CLINICAL TRIALS CONTRACTED REVENUE
25,000,000
Cogstate now has a pipeline of
contracted Clinical Trials revenue
totaling A$15.3m to be
recognised in FY17
20,000,000
Contracted revenue for FY17 is
already 40% ahead of where we
started FY16
15,000,000
10,000,000
5,000,000
FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY19 FY20 FY21
Revenue contracted at beginning of year
© 2015 Cogstate Ltd. All rights reserved.
Revenue from contracts signed during the year
*As at 17 February 2016
15
BUSINESS OUTLOOK: H2 FY16
Maintain prior guidance for a return to positive EBIT in FY16,
with positive EBIT also expected in 2H16
Management are targeting Gross Profit margins of 57%-60%
Based on contracted revenue position as well as positive market
sentiment, management expects continued revenue growth in
2H16
© 2015 Cogstate Ltd. All rights reserved.
16
APPENDIX 1 – CONTRACTED REVENUE PIPELINE
US$20.6m of new sales contracts signed since 1 July 2015 have added an
additional A$12.4m to FY16 contracted revenue. This is in addition to the
A$10.9m that was secured at 1 July 2015:
As at
17 Feb 2016
As at
30 June 2015
As at
18 Feb 2015
Year 1
FY16
A$23.3m FY16
A$10.9m FY15
A$12.0m
Year 2
FY17
A$15.3m FY17
A$ 6.5m
A$ 5.5m
Year 3-5
FY18-FY20
A$13.5m FY18-FY20
A$ 4.0m FY17-FY20
A$ 7.9m
A$52.1m
A$21.4m
A$25.4m
Total
FY16
1. Contracts are denominated in US$. Spot rate at respective dates have been used to calculate the A$ equivalent. The rate used at 17 February 2016 was
0.718, 30 June 2015 was 0.765 and18 February 2015 was 0.78.
© 2015 Cogstate Ltd. All rights reserved.
18
APPENDIX 2 –CONTRACTS SIGNED VS. REVENUE
14
12
10
A$ millions
8
6
4
2
Contracts Signed
© 2015 Cogstate Ltd. All rights reserved.
Dec-15
Sep-15
Jun-15
Mar-15
Dec-14
Sep-14
Jun-14
Mar-14
Dec-13
Sep-13
0
Revenue Recognised
19
APPENDIX 3 –CONTRACTS SIGNED VS. REVENUE
QUARTERLY BOOK-TO-BILL RATIO
4.50
4.00
3.50
Future Growth
CONTRACTS / REVENUE
New contract signings in
2Q16 of A$11.4m exceeded
the A$6.5m of revenue in
the same period by 1.77x
(Book-to-Bill ratio). This is
the sixth consecutive
quarter where new contract
signings have exceeded
revenue (Book-to-Bill ratio
>1), indicating ongoing
growth in the revenue
pipeline.
3.00
2.50
2.00
1.50
1.00
0.50
0.00
At 1.00, contracts signed = revenue and future contracted
revenue is constant.
When Book-to-Bill > 1.00 contracted future revenue
increases.
© 2015 Cogstate Ltd. All rights reserved.
20
APPENDIX 4 - SUMMARY BALANCE SHEET
31 DEC 2015
A$’000,000
30 JUN 2015
A$’000,000
- Cash and cash equivalents
5.09
5.50
- Trade and other receivables
6.68
4.90
- Other current assets
1.15
0.46
- Property, plant and equipment
1.99
1.12
- Deferred tax assets
3.55
1.94
- Intangible assets
0.40
0.40
18.86
14.31
- Trade and other payables
3.72
2.55
- Provisions
1.35
1.15
- Deferred tax liabilities
0.58
0.49
Total Liabilities
5.65
4.19
Net Assets
13.21
10.11
Assets
Total Assets
Liabilities
© 2015 Cogstate Ltd. All rights reserved.
21
APPENDIX 5 - BOARD OF DIRECTORS
•
MARTYN MYER AO - Chairman
Founder with long history of supporting neurosciences in Aust.
•
DAVID DOLBY - Non-Executive Director
Director Dolby Laboratories Inc. and Dolby Family Ventures, an early stage venture firm focused on
building great technology companies.
•
DAVID SIMPSON - Independent Non-Executive Director
Previously Senior Partner at Doremus Communications, the largest US business to business
advertsing agency. From 1985 to 2001 he held a series of senior management positions in Asia,
South Africa and North America as well as Australia for the multinational advertising agency, J.Walter
Thompson.
•
RICHARD VAN DEN BROEK - Independent Non-Executive Director
Founder and managing partner of HSMR Advisors LLC, a U.S. based fund manager with an
investment emphasis on small and mid-cap biotech public companies
•
BRAD O’CONNOR – CEO
CEO since December 2005
© 2015 Cogstate Ltd. All rights reserved.
22
Share your feedback
Discover